Clinical evidence has demonstrated:
The SWOG-8814 study established the Oncotype DX test as predictive of CT benefit in node-positive postmenopausal patients.
Another recent study published in 2023 shows that the Oncotype DX test increases confidence and concordance among oncologists in adjuvant chemotherapy recommendations for early-stage breast cancer.
The study concludes that:
In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify a significant proportion of node-positive patients (with up to 3 positive nodes) who may not benefit from the addition of chemotherapy.
The Oncotype DX Breast Recurrence Score test should be used for:
Adjuvant chemotherapy may be guided with the Oncotype DX Breast Recurrence Score test to identify:
Since clinical risk features alone are not sufficient to determine CT benefit, the Oncotype DX Breast Recurrence Score test should be used for: